Efficacy of imiquimod, an immunomodulatory agent, on experimental endometriosis

Objective To investigate the efficacy of imiquimod on endometriosis. Design Randomized, placebo-controlled, single-blind, experimental study. Setting Experimental surgery laboratory at a university in Turkey. Animal(s) Thirty Wistar female rats. Intervention(s) After the peritoneal implantation of e...

Full description

Saved in:
Bibliographic Details
Published in:Fertility and sterility 2008-08, Vol.90 (2), p.401-405
Main Authors: Altintas, Devrim, M.D, Kokcu, Arif, M.D, Kandemir, Bedri, M.D, Cetinkaya, Mehmet B., M.D, Tosun, Migraci, M.D
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - therapeutic use
Aminoquinolines - therapeutic use
Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Disease Models, Animal
Endometriosis - drug therapy
Endometriosis - pathology
Endometrium - drug effects
Endometrium - pathology
experimental endometriosis
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Imiquimod
Immunomodulators
immunomodulatory agent
Internal Medicine
Medical sciences
Non tumoral diseases
Obstetrics and Gynecology
Pharmacology. Drug treatments
Random Allocation
rat
Rats
Rats, Wistar
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To investigate the efficacy of imiquimod on endometriosis. Design Randomized, placebo-controlled, single-blind, experimental study. Setting Experimental surgery laboratory at a university in Turkey. Animal(s) Thirty Wistar female rats. Intervention(s) After the peritoneal implantation of endometrial tissue, rats were randomized to two equal intervention groups: [1] the control group and [2] the imiquimod group. Six weeks later, after implant volume was measured (volume 1) by performing a second laparotomy, imiquimod (10 mg intraperitoneally per rat, 2 times per wk) was administered to the imiquimod group, and saline solution (0.1 mL SC, once per wk), to the control group, for 8 weeks. At the end of the treatment, a third laparotomy was performed to remeasure implant volumes (volume 2), and implants were totally excised for histopathologic examination. Main Outcome Measure(s) To compare volume 1 and volume 2 within the groups, as well as stromal and glandular tissues between the groups. Result(s) In the imiquimod group, volume 2 was statistically significantly reduced compared with volume 1, whereas there was no significant volume change in the control group. In the imiquimod group, when compared with the control group, both glandular and stromal tissues had statistically significantly lessened. Conclusion(s) Imiquimod was seen to regress significantly both the size and the histological structure of endometriotic implants.
ISSN:0015-0282
1556-5653
DOI:10.1016/j.fertnstert.2007.06.057